General obstetrics and gynecology
Safety of metronidazole in pregnancy: A meta-analysis

https://doi.org/10.1016/0002-9378(95)90567-7Get rights and content

Abstract

OBJECTIVE: Our purpose was to determine from published experience in humans whether metronidazole exposure during the first trimester of pregnancy is associated with an increased teratogenic risk.

STUDY DESIGN: All published articles reporting on metronidazole use during pregnancy were screened by two independent reviewers to select those including pregnant patients exposed during the first trimester and comparing the outcomes of their pregnancies with that of patients either not exposed to metronidazole or exposed only during the third trimester. The outcome under consideration was the occurrence of birth defects in live-born infants. The overall odds ratios of first-trimester exposure versus no first-trimester exposure was calculated by combining the selected studies in a meta-analysis according to the procedure of Mantel and Haenszel.

RESULTS: From 32 identified studies, 7 met the inclusion criteria for meta-analysis. Six were prospective and included 253 women exposed to the drug in the first trimester of pregnancy; one was retrospective and reported on 1083 exposed women. The overall weighted odds ratio of exposure versus no exposure during the first trimester calculated by meta-analysis of the 7 studies was 0.93 (95% confidence interval 0.73 to 1.18). The odds ratio calculated from the 6 prospective studies was 1.02 (95% confidence interval 0.48 to 2.18).

CONCLUSION: Metronidazole does not appear to be associated with an increased teratogenic risk.

References (22)

  • JG Lossick et al.

    Trichomoniasis: trends in diagnosis and management

    Am J Obstet Gynecol

    (1991)
  • SC Robinson et al.

    Trichomonas vaginalis. V. Further observations on metronidazole (including infant follow-up)

    Am J Obstet Gynecol

    (1965)
  • W Peterson et al.

    Metronidazole in pregnancy

    Am J Obstet Gynecol

    (1966)
  • L Heisterberg

    Placental transfer of metronidazole in the first trimester of pregnancy

    J Perinat Med

    (1984)
  • JFC Roe

    A critical appraisal of the toxicology of metronidazole

  • CM Beard et al.

    Lack of evidence for cancer due to use of metronidazole

    N Engl J Med

    (1979)
  • JM Cantu et al.

    Midline facial defect as a teratogenic effect of metronidazole

    Birth Defects

    (1982)
  • F Greenberg

    Possible metronidazole teratogenicity and clefting

    Am J Med Genet

    (1985)
  • A Berget et al.

    Metronidazole and pregnancy

    Ugeskri Laeger

    (1972)
  • ME Royer

    Innocuité du métronidazole prescrit pendant la grossesse

    Med Maladie Infect

    (1983)
  • JL Schardein

    Chemically induced birth defects

  • Cited by (276)

    • Fertility and Pregnancy in Crohn's Disease

      2022, Gastroenterology Clinics of North America
      Citation Excerpt :

      Fluoroquinolones have a theoretic risk of causing cartilage damage and arthropathies in the fetus when taken during pregnancy based on animal studies; however, subsequent meta-analyses do not support these findings.62,66 Short courses of nitroimidazoles seem to be safe for the mother and infant.67 Women who are taking thiopurines before conception to maintain remission can safely continue their use throughout pregnancy.

    • Investigating the efficacy and safety of metronidazole during pregnancy; A systematic review and meta-analysis

      2021, European Journal of Obstetrics and Gynecology and Reproductive Biology: X
      Citation Excerpt :

      Moreover, the robustness of our results was proved using sensitivity analyses that produced findings similar to the original analyses. Compared to two previous meta-analyses of 1995 [20] (7 studies) and 1997 [21] (5 studies) on malformations, our meta-analysis is an update of 12 studies with 411,380 participants. Furthermore, this is the first meta-analysis to consider the assessment of risks related to MET exposure in light of the dose, duration, route of administration, indication and the period of exposure of the treatment.

    • Gastrointestinal disorders

      2021, Clinical Pharmacology During Pregnancy
    • Bacterial vaginosis in pregnancy – a storm in the cup of tea

      2020, European Journal of Obstetrics and Gynecology and Reproductive Biology
    View all citing articles on Scopus
    1

    Dr. Burtin was supported by a grant from the Association Française pour la Recherche Thérapeutique, Paris, France

    2

    Dr. Koren is a Career Scientist of the Ontario Ministry of Health.

    View full text